Show Summary Details
Page of

Cancer in a renal transplant recipient 

Cancer in a renal transplant recipient
Chapter:
Cancer in a renal transplant recipient
Author(s):

Christine Parkinson

and Thankamma Ajithkumar

DOI:
10.1093/med/9780199664535.003.0020
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 August 2019

Cancer is a well-known complication of organ transplantation. Cancer can occur de novo, as a recurrence of pre-existing malignancy, or from transmission of cancer from the donor. The most common de novo transplant-associated cancers are those of the skin and lymphoreticular system. Management of cancer in transplant patients poses a unique challenge. Principles of cancer management are similar to non-transplant patients but need to be modified to avoid the risk of a graft loss. Generally, there is no contraindication to surgery. Delivery of radiotherapy can be challenging particularly when tumour is in close proximity to the allograft. Chemotherapy is associated with an increased risk of graft loss due to direct cytogenetic effects, as a result of interactions with anti-rejection drugs, and an increased risk of sepsis. Therefore, immunosuppressants and chemotherapy may need to be modified in cancer patients with allografts.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.